BioCatalystWatch
MGNXWorkspace / MGNX / OverviewCompany library
Price
Market cap
Next catalystPreliminary MGC028 dose-escalation results in late 2026MGC028 — advanced solid tumors · Data readoutSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

MGC026

B7-H3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MGC026

B7-H3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

MGC030

PreINDP1P2P3FilingApproved
Upcoming / outlook

MGC026

B7-H3

PreINDP1P2P3FilingApproved
MGC026

B7-H3

PreINDP1P2P3FilingApproved
MGC026

B7-H3

PreINDP1P2P3FilingApproved
MGC028

ADAM9

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved
Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved
Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved
Lorigerlimab

PD-1 × CTLA-4

lead research molecule

CD3

PreINDP1P2P3FilingApproved
bispecific CD25 × CTLA-4 DART molecule

CD25 × CTLA-4

PreINDP1P2P3FilingApproved

Partner / License out

PD-1

PreINDP1P2P3FilingApproved

Approved / commercial

CD3ε

Approved

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved

CD3

Approved

PreINDP1P2P3FilingApproved

History / paused

B7-H3

PreINDP1P2P3FilingApproved

B7-H3

PreINDP1P2P3FilingApproved
Lorigerlimab

PD-1 × CTLA-4

PreINDP1P2P3FilingApproved

B7-H3

PreINDP1P2P3FilingApproved

B7-H3

B7-H3

PreINDP1P2P3FilingApproved

B7-H3

CD123 × CD3

PreINDP1P2P3FilingApproved

PD-1 × LAG-3

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MGNX PR & News

PR & News

MGNX SEC archive